Mind Medicine News

Mind Medicine (MindMed) Inc. (MNMD) Q1 2024 Earnings Call Transcript Summary

The following is a summary of the Mind Medicine (MindMed) Inc. (MNMD) Q1 2024 Earnings Call Transcript:Financial Performance:Mind Medicine raised approximately $175 million from an oversubscribed unde

Futu NewsMay 10 00:22 · Conference Call

Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S.

-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life--People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed

BenzingaMay 9 20:56

Mind Medicine Inc (MNMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic Advances Amid ...

Yahoo FinanceMay 9 15:38

Mind Medicine Retained Executive Search Firm to Assist in Identifying a New CFO

Mind Medicine Retained Executive Search Firm to Assist in Identifying a New CFO

Dow JonesMay 9 04:30

Mind Medicine Made Transition in CFO Role Resulting in Departure of Schond Greenway >MNMD

Mind Medicine Made Transition in CFO Role Resulting in Departure of Schond Greenway >MNMD

Dow JonesMay 9 04:29

10-Q: Quarterly report

Futu NewsMay 9 04:21 · Announcements

Mind Medicine Q1 2024 GAAP EPS $(1.14) Misses $(0.53) Estimate

Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(0.53) by 115.09 percent. This is a 75.38 percent decrease over losses of $(0

BenzingaMay 9 04:03

Mind Medicine MindMed 1Q Loss/Shr $1.14 >MNMD

Mind Medicine MindMed 1Q Loss/Shr $1.14 >MNMD

Dow JonesMay 9 04:03

"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment

The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), scheduling a meeting next mon

BenzingaMay 7 23:54

MindMed Releases Promising Phase 2 Data on LSD-related Anxiety Therapy

Seeking AlphaMay 7 00:16

Reported Saturday, MindMed Unveils Phase 2b Data Of MM120 For Generalized Anxiety Disorder At American Psychiatric Association Annual Meeting

-A single oral administration of MM120 100 μg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with

BenzingaMay 6 15:47

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

-A single oral administration of MM120 100 μg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical

BusinesswireMay 4 20:00

Press Release: MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update

MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update NEW YORK--(BUSINESS WIRE)--May 02, 2024-- Mind Medicine (MindMed) Inc. (NASDAQ

Dow JonesMay 2 19:14

Psychedelic Drug Developers Could Benefit From NIH Funding for Chronic Pain

Seeking AlphaApr 30 01:37

MindMed to Present at Upcoming May Medical Conferences

Stockhouse Apr 25 19:00

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati

BenzingaApr 17 21:13

Mind Medicine Initiated at Outperform by Leerink Partners

Mind Medicine Initiated at Outperform by Leerink Partners

Dow JonesApr 15 22:39

Mind Medicine (MNMD.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $20.00.

Mind Medicine (MNMD.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $20.00.

Zhitong FinanceApr 15 22:31

Leerink Partners Initiates Coverage On Mind Medicine With Outperform Rating, Announces Price Target of $20

Leerink Partners analyst Rudy Li initiates coverage on Mind Medicine (NASDAQ:MNMD) with a Outperform rating and announces Price Target of $20.

BenzingaApr 15 22:30

Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.

BenzingaApr 10 22:56